Adaptive Biotechnologies Corp (ADPT) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $28.37 (-0.63%), Market cap $2.08B, 52-week low–high $8.84 ~ $20.46.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications.
Financial statements, price targets, institutional (13F) holdings and related news for Adaptive Biotechnologies Corp are updated in real time on BlackAll Trade.
Adaptive Biotechnologies Corp trades at $28.37 (-0.63%). Real-time quotes and charts are available on BlackAll Trade.
Adaptive Biotechnologies Corp has a market cap of about $2.08B.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform